FNY Investment Advisers’s Sarepta Therapeutics SRPT Stock Holding History

FNY Investment Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25	Closed	-$1K	–	1275
2018 Q2	$1K	Buy	+25	New	+$2.36K	﹤0.01%	977

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FNY Investment Advisers's SRPT Position: Q4 2025 in Review

FNY Investment Advisers sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 14 shares.

FNY Investment Advisers first reported a position in SRPT in Q2 2018 and held it in 9 quarters. The position peaked at $574K in Q2 2019. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

FNY Investment Advisers reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
FNY Investment Advisers sold 14 Sarepta Therapeutics shares in Q4 2025.
FNY Investment Advisers first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 9 quarters.
FNY Investment Advisers's Sarepta Therapeutics position peaked at $574K in Q2 2019.
346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.